Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Buy" from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has earned an average recommendation of "Buy" from the nine ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $211.13.

A number of analysts recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup reduced their target price on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Finally, HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, May 6th.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of KRYS. FMR LLC boosted its position in shares of Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after acquiring an additional 28,707 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after buying an additional 365,304 shares in the last quarter. Finally, Hood River Capital Management LLC grew its position in Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Trading Up 4.7%

KRYS stock traded up $5.91 during midday trading on Friday, hitting $131.27. The stock had a trading volume of 177,326 shares, compared to its average volume of 309,593. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of 43.90 and a beta of 0.79. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $219.34. The stock has a 50-day simple moving average of $153.63 and a 200 day simple moving average of $164.26.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. On average, equities analysts forecast that Krystal Biotech will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).